Pfizer and BioNTech Sign Vaccine Agreement with EU

Pfizer and BioNTech Sign Vaccine Agreement with EU Pfizer and BioNTech sign vaccine agreement with EU. The companies in question agreed with the EU to supply 200 million vaccines. Pfizer and BioNTech signed a preliminary agreement to supply 200 million doses of the vaccine, they are still in the trial phase to the European Union (EU). Accordingly, US and German partners have received the most pre-orders ever.   According to the statement made today, the European Commission held preliminary talks; It is reported that the negotiation stage has been reached for the contract. On the other hand, the EU has not yet announced the financial terms of the agreement. In addition, the deal includes the option to order an extra 100 million doses. According to the companies' statement, the vaccine will be ready for evaluation by regulatory agencies in October. In addition, companies registered 25 thousand of 30 thousand participants for large-scale clinical trials and received guarantees from regulatory organizations to expand the scope of the studies to Germany. Vaccines produced by these companies involve the production of a protein that will strengthen the immune system by stimulating the cells in the body.